Table 4. Interaction between regular exercise and PITX1 genetic variant in the risk of CRC stratified by anatomical sites and gender.
| Regular exercise | CC | AC/AA | p–interaction | ||
|---|---|---|---|---|---|
| No | Yes | No | Yes | ||
| Colorectal cancer | |||||
| All | |||||
| No. controls/cases | 295/197 | 373/97 | 239/265 | 417/128 | |
| Crude OR (95% CI) | 1.00 (ref.) | 0.39 (0.29–0.52) | 1.66 (1.29–2.13) | 0.46 (0.35–0.60) | 0.086 |
| Adjusted ORa (95% CI) | 1.00 (ref.) | 0.45 (0.32–0.62) | 1.81 (1.37–2.41) | 0.48 (0.36–0.65) | 0.018 |
| Male | |||||
| No. controls/cases | 191/132 | 278/74 | 149/169 | 285/94 | |
| Crude OR (95% CI) | 1.00 (ref.) | 0.39 (0.27–0.54) | 1.64 (1.20–2.24) | 0.48 (0.35–0.66) | 0.238 |
| Adjusted ORb (95% CI) | 1.00 (ref.) | 0.45 (0.30–0.66) | 1.69 (1.18–2.41) | 0.52 (0.36–0.75) | 0.173 |
| Female | |||||
| No. controls/cases | 104/65 | 95/23 | 90/96 | 132/34 | |
| Crude OR (95% CI) | 1.00 (ref.) | 0.39 (0.22–0.67) | 1.71 (1.12–2.61) | 0.41 (0.25–0.67) | 0.204 |
| Adjusted ORb (95% CI) | 1.00 (ref.) | 0.45 (0.24–0.83) | 1.99 (1.23–3.22) | 0.40 (0.23–0.70) | 0.055 |
| Colon cancer | |||||
| All | |||||
| No. controls/cases | 295/90 | 373/56 | 239/130 | 417/73 | |
| Crude OR (95% CI) | 1.00 (ref) | 0.49 (0.34–0.71) | 1.78 (1.30–2.45) | 0.57 (0.41–0.81) | 0.091 |
| Adjusted ORa (95% CI) | 1.00 (ref) | 0.57 (0.38–0.84) | 1.95 (1.38–2.75) | 0.38 (0.26–0.56) | 0.029 |
| Male | |||||
| No. controls/cases | 191/57 | 278/42 | 149/78 | 285/52 | |
| Crude OR (95% CI) | 1.00 (ref) | 0.51 (0.33–0.79) | 1.75 (1.17–2.63) | 0.61 (0.40–0.93) | 0.220 |
| Adjusted ORb (95% CI) | 1.00 (ref) | 0.58 (0.36–0.94) | 1.81 (1.17–2.80) | 0.67 (0.43–1.06) | 0.149 |
| Female | |||||
| No. controls/cases | 104/33 | 95/14 | 90/52 | 132/21 | |
| Crude OR (95% CI) | 1.00 (ref) | 0.46 (0.23–0.92) | 1.82 (1.08–3.06) | 0.50 (0.27–0.92) | 0.254 |
| Adjusted ORb (95% CI) | 1.00 (ref) | 0.53 (0.25–1.11) | 2.13 (1.20–3.78) | 0.48 (0.25–0.95) | 0.131 |
| Rectal cancer | |||||
| All | |||||
| No. controls/cases | 295/106 | 373/40 | 239/128 | 417/55 | |
| Crude OR (95% CI) | 1.00 (ref) | 0.30 (0.20–0.44) | 1.49 (1.10–2.03) | 0.37 (0.26–0.53) | 0.478 |
| Adjusted ORa (95% CI) | 1.00 (ref) | 0.34 (0.22–0.52) | 1.63 (1.17–2.29) | 0.38 (0.26–0.56) | 0.277 |
| Male | |||||
| No. controls/cases | 191/74 | 278/32 | 149/89 | 285/42 | |
| Crude OR (95% CI) | 1.00 (ref) | 0.30 (0.19–0.47) | 1.54 (1.06–2.24) | 0.38 (0.25–0.58) | 0.555 |
| Adjusted ORb (95% CI) | 1.00 (ref) | 0.35 (0.21–0.57) | 1.59 (1.05–2.40) | 0.41 (0.26–0.65) | 0.483 |
| Female | |||||
| No. controls/cases | 104/32 | 95/8 | 90/39 | 132/13 | |
| Crude OR | 1.00 (ref) | 0.27 (0.12–0.62) | 1.41 (0.82–2.43) | 0.32 (0.16–0.64) | 0.735 |
| Adjusted ORb | 1.00 (ref) | 0.33 (0.14–0.79) | 1.65 (0.92–2.97) | 0.33 (0.16–0.69) | 0.550 |
aAdjusted for age, gender, education, alcohol, family history of CRC, total energy intake.
bAdjusted for age, education, alcohol, family history of CRC, total energy intake.